Associated Genetic Biomarkers
NCI Definition: A common cancer characterized by the presence of malignant glandular cells. Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous). Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma. 
Adenocarcinomas most frequently harbor alterations in TP53, KRAS, APC, PIK3CA, and EGFR .
TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, KRAS Mutation, and KRAS Exon 2 Mutation are the most common alterations in adenocarcinoma .
There are 7 clinical trials for adenocarcinoma, of which 6 are open and 1 is completed or closed. Of the trials that contain adenocarcinoma as an inclusion criterion, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open).
Deficient, KRAS, and MLH1 are the most frequent gene inclusion criteria for adenocarcinoma clinical trials .
Arx517, taa-specific t cells, and atezolizumab are the most common interventions in adenocarcinoma clinical trials.
Significant Genes in Adenocarcinoma
UGT1A1 is an inclusion eligibility criterion in 1 clinical trial for adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains UGT1A1 status and adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.